NICE publishes recommendation for Novartis drug Afinitor® (everolimus) in its final draft guidance to treat unresectable or metastatic neuroendocrine tumours in patients with progressive disease
May 26, 2017
NICE recommendation helps fulfil unmet need for rare cancer patients by recommending access to targeted therapy
NICE recognises Afinitor as an option for treating well- or moderately-differentiated unresectable or metastatic neuroendocrine tumours (NETs) of pancreatic origin in adults with progressive disease1
Afinitor is recommended as an option for treating well-differentiated (grade 1 or grade 2) non-functional unresectable or metastatic NETs of gastrointestinal or lung origin in adults with progressive disease1
Camberley, UK, May 30 2017 – Novartis announced today that NICE has recommended Afinitor® (everolimus) in its final draft guidance for the treatment of well- or moderately-differentiated unresectable or metastatic neuroendocrine tumours (NETs) of pancreatic origin in adults with progressive disease. NICE also recommended Afinitor for the treatment of well-differentiated (grade 1 or grade 2) non-functional unresectable or metastatic NETs of gastrointestinal or lung origin in adults with progressive disease1. The NICE Technology Appraisal Guidance, the final step within the NICE approval process, is scheduled for publication in June 2017 and will be available via the NICE website.
Everolimus targets mTOR, a protein that acts as an important regulator of tumour cell division, blood vessel growth and cell metabolism1. Clinical data have established the role of mTOR in the development and progression of several types of tumours, including renal cell carcinoma and breast cancer for which it is already available in the UK1. Everolimus has now been proven to slow progression of NETs of GI, lung or pancreatic origin and is the first mTOR inhibitor available in the UK for the treatment of this disease2.
NETs are tumours that develop in the cells of the neuroendocrine system and can be found in different organs, such as bowel, stomach or lungs1. NETs are unpredictable and complex to treat, with multiple specialties involved in the management of this disease. This recommendation means that patients now have access to a targeted therapy treatment and recognises the positive effect Afinitor can have on delaying disease progression for this group of patients.
Barak Palatchi, General Manager Novartis Oncology UK & Ireland said: “We are pleased that NICE has recognised the value Afinitor brings to patients with a rare form of cancer. Our ongoing collaboration with NICE highlights our commitment to ensuring patients have access to much needed treatments.”
“Neuroendocrine tumours have a unique genetic make-up and ideally patients need to have an individualised approach to treatment options to ensure the best outcomes. Historically there have been few licensed treatment options available to GI and pancreatic NET patients and inadequacies in treatment options for lung NET patients, so the availability of targeted treatments such as Afinitor for these patients is positive news,” said Catherine Bouvier, CEO, NET Patient Foundation.
Novartis provides innovative healthcare solutions that address the evolving needs of patients and societies. Headquartered in Basel, Switzerland, Novartis offers a diversified portfolio to best meet these needs: innovative medicines, cost-saving generic and biosimilar pharmaceuticals and eye care. Novartis has leading positions globally in each of these areas. In 2016, the Group achieved net sales of USD 48.5 billion, while R&D throughout the Group amounted to approximately USD 9.0 billion. Novartis Group companies employ approximately 118,000 full-time-equivalent associates. Novartis products are sold in approximately 155 countries around the world. For more information, please visit http://www.novartis.com.
In the UK, Novartis develops, manufactures and markets innovative medicines, devices and diagnostic tests which help improve patient outcomes. Based on four sites across the north and south of England, we employ approximately 1,500 people to serve healthcare needs across the whole of the UK, as well as supporting the global operations of Novartis by manufacturing the active pharmaceutical ingredients used worldwide in many medicines. In 2015 Novartis in the UK invested over £50million in R&D and is the largest commercial sponsor of clinical trials. For more information, please visit www.novartis.co.uk.